# Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

> **NCT00674583** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 414 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** GSK Biologicals' meningococcal vaccine GSK134612
- **BIOLOGICAL:** Menjugate

## Key facts

- **NCT ID:** NCT00674583
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-09
- **Primary completion:** 2008-09-02
- **Final completion:** 2009-01-08
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674583, "Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00674583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*